With new hope for a two-year reimbursement extension for Omidria, Jason McCarthy now bets on 58% in return potential for the stock.
H.C.
OMER shares may be seeing a pullback today, but this bull believes the drug maker has a standout product profile in its kidney asset that can save patient lives.
So what to make of Omeros Corporation’s (NASDAQ:OMER) latest success? This morning, the drug maker announced that it has reached an agreement with …
Maxim’s Jason Kolbert is keeping his focus peeled to the Omeros pipeline, even though he welcomes the FDA victory for Omidria.
Cantor’s Elemer Piros waits for pass-through reimbursement to be address, before joining the ‘Omeros party’.
Omeros Corporation (NASDAQ:OMER) shares are on fire this evening, rising nearly 11%, after the drug maker reported better-than-expected 3Q Omidria sales. Third Quarter Highlights 3Q …
Omeros Corporation (NASDAQ:OMER) announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at …
Jason Kolbert believes that OMER’s OMS721 flashes an upper hand over competitor Soliris drug.
Drug maker Omeros Corporation (NASDAQ:OMER) announced that it entered into a settlement agreement with Par Pharmaceutical and its subsidiary Par Sterile Products, resolving …
